Orientinine and dehydroisothebaine ? New alkaloids fromPapaver orientale
作者:I. A. Israilov、M. A. Manushakyan、V. A. Mnatsakayan、M. S. Yunusov、S. Yu. Yunusov
DOI:10.1007/bf00579507
日期:——
COMPOSITIONS AND METHODS RELATING TO HINDERING DOT1L RECRUITMENT BY MLL-FUSION PROTEINS
申请人:The Regents of the University of Michigan
公开号:US20150368300A1
公开(公告)日:2015-12-24
The present invention relates to MLL fusion proteins (e.g., AF9 and ENL), which activate target genes in part via recruitment of histone methyltransferase DOT1L. In particular, the present invention provides the AF9/ENL binding site in DOT1L and agents that block the protein-protein interactions between AF9/ENL and DOT1L, therefore inhibiting the activity of DOT1L, and inhibiting MLL-fusion protein associated leukemia.
US4309542A
申请人:——
公开号:US4309542A
公开(公告)日:1982-01-05
US9862746B2
申请人:——
公开号:US9862746B2
公开(公告)日:2018-01-09
[EN] COMPOSITIONS AND METHODS RELATING TO HINDERING DOT1L RECRUITMENT BY MLL-FUSION PROTEINS<br/>[FR] COMPOSITIONS ET MÉTHODES EMPÊCHANT LE RECRUTEMENT DE DOT1L PAR LES PROTÉINES HYBRIDES MLL
申请人:UNIV MICHIGAN
公开号:WO2014127191A1
公开(公告)日:2014-08-21
The present invention relates to MLL fusion proteins (e.g., AF9 and ENL), which activate target genes in part via recruitment of histone methyltransferase DOT1L. In particular, the present invention provides the AF9/ENL binding site in DOT1L and agents that block the protein-protein interactions between AF9/ENL and DOT1L, therefore inhibiting the activity of DOT1L, and inhibiting MLL-fusion protein associated leukemia.